In 2016, about 14,000 patients in the United States are expected to be diagnosed with high grade glioma, a highly aggressive form of brain cancer.
Gleolan® is a real time real intra-operative imaging agent that assists surgeons by improving the visualization of Glioblastoma multiforme (GBM) tumors before resection.
GBM is an Orphan indication that is highly valued target for Pharma and emerging Life Science companies.
In excess of 100 clinical trials are currently focused on either salvage therapy or frontline attempts to impact on this universally lethal disease.
Several high valued drugs are “blockbusters” (~$1BN sales) in the 10,000 new GBM patients each year.
Pharmacoeconomic models indicate significant savings to healthcare systems and individual payers.
Gleolan’s Increased progression free survival and overall survival with improved resection can reflect up to 20% increase in blockbuster sales opportunity for Temodar®, Avastin®, emerging Immunotherapeutics in the affected population.
Synergistic benefits reported for Gleolan® with new Immunotherapeutics.
New opportunities in other CNS and solid tumors cancers are added value.
Additional Information »